On August 15, 2025, ResMed Inc. announced the election of Nicole Mowad-Nassar to its board of directors. Mowad-Nassar, who is currently the Senior Vice President at AbbVie Inc., brings extensive experience in commercial strategy and operations from her previous roles. She will serve on the Compensation and Leadership Development Committee and will be up for reelection at the 2025 Annual Meeting of Stockholders scheduled for November 19, 2025.
Additionally, Richard Sulpizio, a board member since 2005, will retire and not stand for reelection at the upcoming annual meeting. His departure marks the end of a two-decade tenure during which he contributed to various board committees, including the Compensation Committee. ResMed acknowledged Sulpizio's significant contributions to the company and its governance.
link24min ago
Bobby Ghoshal, the Chief Commercial Officer of ResMed, has announced his resignation effective August 1, 2025. He will be leaving to take on a role as Chief Operating Officer at a software company that operates in a non-competitive industry.
This leadership change may impact ResMed's operations, particularly within its residential care software business. Investors may want to monitor how this transition affects the company's strategic direction and performance in the coming months.
linkJul 31, 2025 18:30:21
On July 31, 2025, ResMed Inc. announced a quarterly cash dividend of $0.60 per share, with a record date of August 14, 2025, and payment scheduled for September 18, 2025. The ex-dividend date is set for August 13, 2025. The company has also received a waiver from the ASX’s settlement operating rules to defer processing conversions between its common stock and CHESS Depositary Interests for the specified dates.
In its financial results for the fourth quarter ended June 30, 2025, ResMed reported a 10% increase in revenue compared to the prior year, along with a 230 basis point expansion in non-GAAP gross margin and a 23% growth in non-GAAP earnings per share. The company attributed this growth to strong global demand for its sleep and breathing health devices and an expanding digital health ecosystem.
linkJul 31, 2025 16:05:17
Resmed Inc. announced its financial results for the third quarter of fiscal year 2025, reporting an 8% increase in revenue to $1.3 billion compared to the same period last year. The company achieved a 14% rise in income from operations and a 140 basis point improvement in gross margin, reaching 59.3%. Operating cash flow for the quarter was $579 million, with diluted earnings per share at $2.48. The growth was attributed to strong demand for sleep devices and solid performance in the Residential Care Software business.
In addition to financial results, Resmed introduced its home sleep apnea test, NightOwl™, across the U.S. and shared findings from its Global Sleep Survey highlighting a significant global sleep crisis. The company declared a quarterly cash dividend of $0.53 per share, with a record date of May 8, 2025. Resmed's ongoing efforts include enhancing brand visibility and addressing the healthcare needs of individuals with sleep and breathing health issues, indicating a commitment to maintaining growth in its market.
linkApr 23, 2025 16:05:31
ResMed Inc. reported a 10% increase in revenue, reaching $1.3 billion, and a significant 52% rise in operating profit for the second quarter of fiscal year 2025. The company also noted a gross margin improvement of 300 basis points to 58.6% and an operating cash flow of $309 million. Non-GAAP diluted earnings per share increased by 29% to $2.43, driven by strong sales growth and operational efficiencies. Additionally, the company announced a quarterly cash dividend of $0.53 per share and highlighted its commitment to expanding operations in Singapore.
On the downside, selling, general, and administrative expenses rose by 9% on a constant currency basis, primarily due to increased employee-related costs. Although operating income increased significantly, it is important to note that the prior year's results included restructuring charges, which may have impacted the year-over-year comparison. The company also faced challenges in managing expenses while continuing to invest in growth initiatives, pointing to a need for careful financial management moving forward.
linkJan 30, 2025 16:05:28
ResMed Inc. announced impressive financial results for the first quarter of fiscal year 2025, with revenue growing by 11% to $1.2 billion compared to the previous year. The company also reported a significant 34% increase in operating profit and a strong operating cash flow of $326 million. The improvements in gross margin and net income reflect effective management and a growing demand for their sleep and respiratory products. Additionally, ResMed celebrated its 35th anniversary and launched a new 2030 strategy aimed at enhancing its market presence and product offerings.
Despite the positive results, there was a 7% increase in selling, general, and administrative expenses, attributed mainly to employee-related costs. However, the company managed to lower SG&A expenses as a percentage of revenue, indicating improved operational efficiency. ResMed's ongoing commitment to innovation was highlighted by the introduction of new patient-centric products, including a fabric mask designed to enhance user comfort. Overall, the results demonstrate ResMed's strong performance and strategic direction in the healthcare technology sector.
linkOct 24, 2024 16:05:51
ResMed has announced the expansion of its board of directors, appointing Christopher DelOrefice, a seasoned healthcare executive and CFO of BD, to enhance its financial and strategic expertise. DelOrefice brings over 30 years of experience from leading companies like Johnson & Johnson and AstraZeneca, which is expected to strengthen ResMed's operations and governance. His appointment is seen positively by the company's leadership, highlighting his proven track record and leadership skills in the healthcare sector.
The addition of DelOrefice increases the board size to 11 members, and he will also serve on the board audit committee. His extensive background in corporate finance and business strategy aligns well with ResMed's mission to innovate healthcare solutions. This strategic move is aimed at bolstering the company's capabilities in managing financial and operational challenges in the evolving healthcare landscape.
linkAug 16, 2024 17:21:58
ResMed Inc. announced a 9% revenue increase and a 38% rise in operating profit for Q4 2024. Operating cash flow reached $440 million, and a 10% dividend increase to $0.53 per share was declared. The company highlighted strong demand for its products and successful cost management. However, rising expenses were noted, albeit at a lower percentage than revenue growth. Overall, the results reflect solid performance, positioning ResMed well in the sleep health market.
linkAug 01, 2024 16:05:55
ResMed Inc. reports a 7% revenue increase, with operating profit up by 25% in the third quarter of fiscal year 2024. Gross margin improved by 260 basis points, operating cash flow reached $402 million, and debt repayments amounted to $220 million. The company's CEO highlighted strong demand for their products and software solutions, emphasizing innovation and customer value. Additionally, new product launches and a global sleep survey were noted. Quarterly dividends of $0.48 per share were declared, payable in June 2024.
linkApr 25, 2024 16:07:05
ResMed Inc. announced a 12% increase in year-over-year revenue, with operating profit down 2% but non-GAAP operating profit up 20%. The company also resumed its share repurchase program, buying back $50 million during the quarter. The CEO highlighted strong growth in device, masks, accessories, and residential care software businesses. Despite a 50 bps contraction in gross margin, non-GAAP gross margin grew 10 bps. The company also introduced a new operating model and announced the retirement of its former President and COO.
linkJan 24, 2024 16:06:01